GOSS Feb 2025 1.000 call
- Simply Wall St.
Several Insiders Invested In Gossamer Bio Flagging Positive News
It is usually uneventful when a single insider buys stock. However, When quite a few insiders buy shares, as it...
- GlobeNewswire
Presenting on the Emerging Growth Conference 75 Day 2 on September 26
MIAMI, Sept. 25, 2024 (GLOBE NEWSWIRE) -- EmergingGrowth.com, a leading independent small cap media portal, announces the schedule of the 75th Emerging Growth Conference on September 25 & 26, 2024. The Emerging Growth Conference identifies companies in a wide range of growth sectors, with strong management teams, innovative products & services, focused strategy, execution, and the overall potential for long-term growth. Register for the Conference here. Submit Questions for any of the presenting
- Business Wire
Gossamer Bio Announces Data Presentations at the European Respiratory Society Congress 2024
SAN DIEGO, August 26, 2024--Gossamer Bio, Inc. (Nasdaq: GOSS), a clinical-stage biopharmaceutical company focused on the development and commercialization of seralutinib for the treatment of pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD), today announced two oral presentations and a poster presentation with data relevant to seralutinib at the European Respiratory Society (ERS) Congress 2024, which takes place from September 7th
